Study S003270

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06893016
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 640
Start: 2025-06-15
Primary completion: 2026-06-15
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Conditions: Obesity
Interventions: DRUG:RAY1225; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 52 [Baseline and Week 52]
Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52 [Baseline and Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.